In brain tumor, Cui et al.60 reported that pharmaceutical inhibition of FTO by a chemical inhibitor (MA2, the ethyl ester form of meclofenamic acid (MA), a US Food and Drug Administration (FDA)-approved nonsteroidal anti-inflammatory drug that was shown to be a selective inhibitor of FTO59) suppresses tumor progression and substantially prolongs the lifespan of glioblastoma (GBM) stem cell (GSC)-grafted mice. This evidence concerns the gene FTO and neoplasm.